BioVaxys Technology Corp.
Canadian Securities ExchangeTotal Valuation
BioVaxys Technology Corp. carries a market capitalization of 2.04M, placing it among publicly traded companies globally.
| Market Cap | 2.04M |
| Enterprise Value | N/A |
Share Statistics
BioVaxys Technology Corp. currently has 29.15M shares outstanding.
| Shares Outstanding | 29.15M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.15 |
| P/TBV Ratio | -0.28 |
| P/FCF Ratio | -0.33 |
| P/OCF Ratio | -0.33 |
Financial Position
BioVaxys Technology Corp. maintains a current ratio of 0.29, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.29 |
| Quick Ratio | 0.12 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -440.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
BioVaxys Technology Corp.'s stock has declined approximately -82.5% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.20.
| Beta (5Y) | N/A |
| 52-Week Price Change | -82.5% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.20 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -4.88M, while operating income came in at -4.88M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -4.88M |
| Pretax Income | -6.32M |
| Net Income | -6.32M |
| EBITDA | -4.88M |
| EBIT | -4.88M |
| Earnings Per Share (EPS) | -0.25 |
Balance Sheet
Total book value stands at -5.05M, with working capital of -2.73M providing operational flexibility.
| Cash & Cash Equivalents | 4,309.00 |
| Total Debt | N/A |
| Net Debt | 129,411.00 |
| Equity (Book Value) | -5.05M |
| Book Value Per Share | -0.20 |
| Working Capital | -2.73M |
Cash Flow
BioVaxys Technology Corp. produced -2.33M in operating cash flow over the past twelve months. After subtracting -1.00 in capital expenditures, free cash flow totaled -2.33M - equivalent to -0.09 per share.
| Operating Cash Flow | -2.33M |
| Capital Expenditures | -1.00 |
| Free Cash Flow | -2.33M |
| FCF Per Share | -0.09 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -418.80 |
| FCF Yield | -302.18 |
Stock Splits
BioVaxys Technology Corp.'s most recent stock split took place on September 11, 2025 with a 10:1 split ratio.
| Last Split Date | 9/11/2025 |
| Split Ratio | 10:1 |
Scores
BioVaxys Technology Corp. posts an Altman Z-Score of -60.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -60.30 |